IL6 and Familial prostate cancer: Antibodies against IL-6 (CNTO 328, siltuximab) or the IL-6 receptor (tocilizumab, REGN-88) have been used in several clinical trials in different tumor entities, including multiple myeloma, ovarian cancer, prostate cancer, and renal cell carcinoma, and have been found to be well tolerated [150,153].